Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: Correlation with KRAS mutation and the presence of endometriosis

Pathology

Volumn 45, Issue 6, 2013, Pages 559-566

  Stewart, Colin J R ^a,b   Walsh, Michael D ^e,f   Budgeon, Charley A ^c,d   Crook, Maxine L ^a   Buchanan, Daniel B ^f  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

Author keywords

Adenocarcinoma; Endometriosis; Immunohistochemistry; KRAS; Molecular; Ovary; Sertoliform

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MUTATION; OVARY TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; ENDOMETRIOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887938523     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283650ad7     Document Type: Article

References (62)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer- shifting the paradigm. Hum Pathol 2011; 42: 918-31.
3. van Gorp T, Amant F, Neven P, et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004; 18: 349-71.
4. Mandai M, Yamaguchi K, Matsumura N, et al. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 2009; 14: 383-91.
5. D'Angelo E, Prat J. Classification of ovarian carcinomas based on pathology and molecular genetics. Clin Trans Oncol 2010; 12: 783-7.
6. Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol 2010. 740968.
7. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis- associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
8. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011; 224: 328- 33.
9. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011; 35: 625-32.
10. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010; 220: 392-400.
11. Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004; 36: 120-8.
12. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011; 24: 1248-53.
13. Prefumo F, Venturini PL, Fulcheri E. Analysis of p53 and c-erbB-2 expression in ovarian carcinomas arising in endometriosis. Int J Gynecol Pathol 2003; 22: 83-8.
14. Catasus L, Bussaglia E, Rodriguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35: 1360-8.
15. Stewart CJR, Leung Y, Walsh MD, Walters RJ, Young JP, Buchanan DD. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol 2012; 43: 1177- 83.
16. Stewart CJR, Brennan B, Chan T, et al. WT1 immunohistochemistry in ovarian endometrioid carcinoma with and without endometriosis. Pathology 2008; 40: 592-9.
17. Banz C, Ungethuem U, Kuban R-J, et al. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent ovarian cancer. Fertil Steril 2010; 94: 1212-7.
18. McCluggage WG. My thoughts on and approach to the typing of ovarian carcinomas. J Clin Pathol 2008; 61: 152-63.
19. Singh N. Synchronous tumours of the female genital tract. Histopathology 2010; 56: 277-85.
20. Pallares J, Bussaglia E, Matinez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005; 18: 719-27.
21. Stewart CJR, Crook ML, Leung YC, Platten M. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod Pathol 2009; 22: 725-33.
22. Stewart CJR, Crook ML, Little L, Louwen K. Correlation between invasive pattern and immunophenotypic alterations in endocervical adenocarcinoma. Histopathology 2011; 58: 720-8.
23. Walsh MD, Cummings MC, Buchanan DD, et al. Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients. Clin Cancer Res 2008; 14: 1692-700.
24. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23: 129-37.
25. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2012. http://www.R-project.org/.
26. Murray SK, Clement PB, Young RH. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol 2005; 29: 157-66.
27. May KE, Villar J, Kirtley S, Kenneddy SH, Becker CM. Endometrial alterations in endometriosis: a systemic review of putative biomarkers. Hum Reprod Update 2011; 17: 637-53.
28. Bondza PK, Maheux R, Akoum A. Insights into endometriosis-associated endometrial dysfunctions: a review. Front Biosci 2009; 1: 415-28.
29. Prowse AH, Manek S, Varma R, et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006; 119: 556-62.
30. Vigano P, Somigliana E, Chiodo I, et al. Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update 2006; 12: 77-89.
31. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 2012; 124: 164-9.
32. Guan B,Wang TL, Shih I-M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodelling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011; 71: 6718-27.
33. Maeda D, Shih I-M. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 2013; 20: 45- 52.
34. Ayhan A, Mao T-L, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012; 22: 1310-5.
35. Samartzis EP, Samartzis N, Noske A, et al. Loss of ARID1A/ BAF250aexpression in endometriosis: a biomarker for risk of carcinogenic transformation. Mod Pathol 2012; 25: 8858-92.
36. Lowery WJ, Schildkraut JM, Akushevich L, et al. Loss of ARID1Aassociated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer 2012; 22: 9-14.
37. Xiao W, Awadallah A, Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol 2012; 5: 642-50.
38. Maeda D, Mao T-L, Fukayama M, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010; 11: 5120-8.
39. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch 2012; 460: 77-87.
40. Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol 2006; 37: 1042-9.
41. Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J. Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001; 10: 116-22.
42. Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J. Low membranous expression of b-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol 2010; 23: 113-22.
43. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. b-catenin expression pattern in stage I and II ovarian carcinomas. Relationship with b-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999; 155: 527-36.
44. Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutical view points. J Clin Pathol 2009; 62: 777-85.
45. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of b-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001; 61: 8247-55.
46. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005; 18: S19-32.
47. Geyer JT, Lopez-Garcia MA, Sanchez-Estavez C, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 2009; 33: 1157-63.
48. Houghton O, Connolly LE, McCluggage WG. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology 2008; 53: 156-65.
49. Saegusa M, Okayasu I. Frequent nuclear b-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001; 194: 59-67.
50. Brachtel EF, Sanchez-Estevez C, Moreno-Bueno G, Prat J, Palacios J, Oliva E. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Pathol 2005; 29: 1322-9.
51. Oliva E, Sarrio D, Brachtel EF, et al. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol 2006; 208: 708-13.
52. Byron SA, Gartside M, Powell MA, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE 2012; 7: e30801.
53. Stewart CJR, Crook ML, Manso L. Fascin expression in low-grade uterine endometrioid adenocarcinoma: correlation with microcystic, elongated and fragmented (MELF)-type alteration at the deep invasive margin. Histopathology 2011; 59: 73-80.
54. Nicolae A, Preda O, Nogales FF. Endometrial metaplasia and reactive changes: a spectrum of altered differentiation. J Clin Pathol 2011; 64: 97- 106.
55. Rosen DG, Cai KQ, Luthra R, Liu J. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol 2006; 19: 1414-20.
56. Lu FI, Gilks CB, Mulligan AM, et al. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int J Gynecol Pathol 2012; 31: 524-31.
57. Liu J, Albarracin CT, Chang K-H, et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol 2004; 17: 75-80.
58. Aysal A, Kamezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol 2012; 36: 163-72.
59. Shannon C, Kirk J, Barnetson R, et al. Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clin Cancer Res 2003; 9: 1387-92.
60. Karamurzin Y, Leitao MM Jr, Soslow RA. Cliniciopathologic analysis of low-stage sporadic ovarian carcinomas. A reappraisal. Am J Surg Pathol 2013; 37: 356-67.
61. Zhao C, Barner R, Vinh TN, McManus K, Dabbs D, Vang R. SF-1 is a diagnostically useful immunohistochemical marker and comparable to other sex cord-stromal tumor markers for the differential diagnosis of ovarian Sertoli cell tumor. Int J Gynecol Pathol 2008; 27: 507-14.
62. Kauppila S, Altinors M, Vare P, Liakka A, Knuuti E, Nissi R. Primary sex cord-like variant of endometrioid adenocarcinoma arising from endometriosis. APMIS 2008; 116: 842-5.